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Human resident cardiac progenitor cells (CPCs) isolated as cardiosphere-derived cells (CDCs) are under clinical evaluation as a
therapeutic product for cardiac regenerative medicine. Unfortunately, limited engraftment and diﬀerentiation potential of
transplanted cells signiﬁcantly hamper therapeutic success. Moreover, maladaptive remodelling of the extracellular matrix
(ECM) during heart failure progression provides impaired biological and mechanical signals to cardiac cells, including CPCs. In
this study, we aimed at investigating the diﬀerential eﬀect on the phenotype of human CDCs of cardiac ﬁbroblast-derived ECM
substrates from healthy or diseased hearts, named, respectively, normal or pathological cardiogel (CG-N/P). After 7 days of
culture, results show increased levels of cardiogenic gene expression (NKX2.5, CX43) on both decellularized cardiogels
compared to control, while the proportion and staining patterns of GATA4, OCT4, NKX2.5, ACTA1, VIM, and CD90-positive
CPCs were not aﬀected, as assessed by immunoﬂuorescence microscopy and ﬂow cytometry analyses. Nonetheless, CDCs
cultured on CG-N secreted signiﬁcantly higher levels of osteopontin, FGF6, FGF7, NT-3, IGFBP4, and TIMP-2 compared to
those cultured on CG-P, suggesting overall a reduced trophic and antiremodelling paracrine proﬁle of CDCs when in contact
with ECM from pathological cardiac ﬁbroblasts. These results provide novel insights into the bidirectional interplay between
cardiac ECM and CPCs, potentially aﬀecting CPC biology and regenerative potential.
1. Introduction
Despite remarkable progress in early diagnosis and preven-
tion, heart failure (HF) is still the leading cause of death in
Western countries [1]. To date, heart transplantation could
be considered the only eﬀective therapeutic strategy for
end-stage HF patients, albeit limited by organ availability
and immunological issues. Accordingly, research has been
focused on the development of alternative therapies able to
repair a damaged heart and restore its function. Cardiac stem
cell niches in postnatal hearts have been described in recent
years [2, 3]. Resident cardiac progenitor cells (CPCs) can be
isolated with several protocols [4] yielding mesenchymal-
like cell populations sharing similar transcriptomic proﬁles
[5]. Human CPCs can be isolated with clinically compliant
protocols [6] and have been tested in few clinical trials as a
promising tool for cardiac regenerative medicine [7, 8].
Unfortunately, despite the positive preclinical results [9, 10],
regenerative medicine still cannot be considered a strong
alternative to transplantation. It has been demonstrated that
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only 5–10% of the injected cells can be detected after 1 day
from the procedure in the damaged myocardium, meaning
that many cells are lost within few hours after injection
[11, 12]. Furthermore, limited engraftment and prolifera-
tion and diﬀerentiation potential of the transplanted cells,
together with the unsuitable ischemic microenvironment
and the progressive myocardial maladaptive remodelling
process, hamper the therapeutic outcome [13, 14]. Therefore,
increasing the engraftment and regenerative potential of
CPCs, as well as their antiremodelling capacities, for exam-
ple, by means of tissue engineering approaches [15, 16] or
pharmacological treatments [14, 17], would be beneﬁcial.
In the heart, the extracellular matrix (ECM) mediates the
connection among cardiomyocytes, cardiac ﬁbroblasts (CFs),
and blood vessels, granting optimal mechanical features and
sustaining cardiac functions [18, 19]. CFs are one of the most
abundant resident noncardiac cell subpopulations in the
heart. These cells produce and secrete ECM components
(e.g., collagens, ﬁbronectin) and, at the same time, maintain
its homeostasis, through the production of matrix metallo-
proteinases (MMPs) and tissue inhibitors of metalloprotein-
ases (TIMPs) [20]. It is well known that an imbalanced
deposition of ECM components and maladaptive ECM
remodelling are detrimental mechanisms contributing to
the progression of HF [21–24]. This eﬀect is due to both
impaired biological and mechanical stimuli on all cardiac
cells, including CPCs. It has been recently described that
cardiac ﬁbroblast-derived ECM from normal or pathological
hearts can aﬀect in many ways proliferation, migration, and
resistance to apoptosis of CPCs [25], but its eﬀects on cardio-
vascular commitment, phenotype, and paracrine properties
of CPCs have not been elucidated yet. The aim of the present
study is to investigate in vitro the molecular and functional
eﬀects elicited on CPC phenotype when cultured on cardiac
ﬁbroblast-derived ECM substrates, in order to better under-
stand the interactions between ECM components and a suit-
able cell product candidate for heart regenerative therapy, as
well as to improve experimental protocols.
2. Materials and Methods
2.1. Cardiac Fibroblast Isolation and Cardiogel Deposition.
Cardiac samples of the right atrial appendage of human
hearts were obtained from both donor (n = 9, mean age
50.4± 4.1 years) and recipient (n = 9, mean age 55.8± 3.1
years) of heart transplantation. Patients (or legally legitimate
relatives/guardians) provided written informed consent, and
specimens were collected without patient identiﬁers follow-
ing protocols approved by Monaldi Hospital, and in
conformity with the principles outlined in the Declaration
of Helsinki. Cardiac extracellular matrix synthesized and
deposited in vitro was prepared as previously described
[26]. Brieﬂy, samples were dissected, minced, and enzymati-
cally digested by incubation in 0.25% trypsin and 0.1% (w/v)
collagenase II (both from Sigma-Aldrich, St. Louis, MO,
USA) for 30 minutes at 37°C. Digestion ceased when double
volume of HBSS (Sigma-Aldrich) supplemented with 10%
fetal bovine serum (FBS) (Sigma-Aldrich) was added. Fur-
ther mechanical disaggregation was achieved by pipetting;
hence, tissue debris and cardiomyocytes were removed by
sequential centrifugation at 100 rcf for 2 minutes, passage
through a 20μm cell strainer, and centrifugation at 400 rcf
for 5 minutes. Isolated ﬁbroblasts, either from normal
(healthy) or from pathological cardiac tissue (from donors
or recipients, resp.), were cultured in DMEM (Sigma-
Aldrich) supplemented with 10% FBS (Sigma-Aldrich) and
maintained in a conﬂuent state for 21 days, to allow extracel-
lular matrix synthesis and deposition. Next, ﬁbroblasts were
removed with a nonenzymatic method. Fibroblasts were
removed by incubation for 1-2 minutes with a solution of
0.25% Triton X-100 and 10mM NH4OH in PBS. Culture
dishes coated with ﬁbroblast-derived matrix, here named
cardiogel, were washed and used for CPC culture.
2.2. Cardiosphere-Derived Cell Culture. CPCs were isolated as
cardiosphere-derived cells (CDCs), as previously described
[27], which are a clinically relevant therapeutic cell popula-
tion [28] of nonhematopoietic stromal cells containing CPCs
[29–31]. CDCs were derived from right atrial appendage
biopsies obtained from three donor patients undergoing elec-
tive cardiac surgery during clinically indicated procedures,
after informed consent, in an institutional review board-
approved protocol at the “Umberto I” Hospital, “La
Sapienza” University of Rome. CDCs were seeded at a
density of 1.25× 104 cells/cm2 in Petri dishes previously
coated with normal or pathological cardiogel (CG-N and
CG-P, resp.). Cells were then cultured for 7 days in com-
plete explant media (CEM) [Iscove’s modiﬁed Dulbecco’s
medium (IMDM) (Sigma-Aldrich) supplemented with 3%
FBS (Sigma-Aldrich), 1% penicillin-streptomycin (Sigma-
Aldrich), 1% L-glutamine (Lonza, Basel, Switzerland), and
0.1mM 2-mercaptoethanol (Gibco, Thermo Fisher Scientiﬁc,
Waltham, MA, USA)], using cells grown on ﬁbronectin-
coated plates at the same density as the control group.
2.3. Immunostaining and Fluorescence Microscopy Analyses.
After 1 week of culture in 3% FBS-CEM on each cardiogel
and on ﬁbronectin-coated control plates, CDCs were ﬁxed
for 10 minutes with 4% paraformaldehyde at 4°C. For immu-
noﬂuorescence, cells were permeabilized with 0.1% Triton X-
100 (Sigma-Aldrich) in PBS with 1% BSA. Nonspeciﬁc anti-
body binding sites were blocked with 10% goat serum
(Sigma-Aldrich) before overnight incubation at 4°C with pri-
mary antibodies: ACTA1, GATA-4, OCT-4, NKX2-5 (all
Abcam, Cambridge, UK), CX43, KDR (all Millipore, MA,
USA), and vimentin (Santa Cruz Biotechnology, Dallas, TX,
USA). After thorough washing, slides were incubated for 2
hours at room temperature with the appropriate Alexa-
conjugated secondary antibodies (Invitrogen, Carlsbad, CA,
USA) and DAPI nuclear dye (Invitrogen). Slides were
mounted in 70% PBS-glycerol. Imaging was performed on a
Nikon Eclipse Ni microscope equipped with VICO system
and NIS-Elements AR 4.30.02 software (Nikon Corporation,
Tokyo, Japan).
2.4. Flow Cytometry Analysis. Cells were grown on CG-N and
CG-P, and the percentage of cells expressing CD90 was
assessed by ﬂow cytometry. Brieﬂy, the cells were harvested
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with gentle trypsin-EDTA treatment and stained with CD90-
FITC (Dianova, Hamburg, DE) antibody diluted to 1 : 100 in
PBS-2% FBS. Samples were analyzed with a FACS Aria II
cytometer (BD Biosciences, San Jose, CA, USA) using Diva
software (version 6.1.1; BD Biosciences). Data was analyzed
with FlowJo software (version 2.5.1; Turku Centre for Bio-
technologies, Turku, Finland, http://www.btk.ﬁ).
2.5. RNA Extraction and Real-Time PCR. Total RNA was
extracted using the miRNeasy Micro Kit (Qiagen, Hilden,
DE) and quantiﬁed using a spectrophotometer. cDNA was
synthesized using 0.5μg RNA, with the High-Capacity
cDNA Reverse Transcription Kit (Life Technologies, Thermo
Fisher Scientiﬁc, Waltham, MA, USA). Real-time qPCR was
performed to assess gene expression, using Power SYBR
Green PCR Master Mix (Life Technologies, Thermo Fisher
Scientiﬁc) and standard thermocycling conditions according
to the manufacturer’s protocol. The relative ratio for each
substrate versus culture on ﬁbronectin was calculated using
the comparative Ct method (2−ΔΔCt) for each patient sample.
The set of genes analyzed and the primers sequences are
listed in Table 1. GAPDH was selected according to the
NormFinder software, as a housekeeping gene.
2.6. Conditioned Medium Screening. After 5 days of culture,
media were changed for the last 24 hours of culture to be col-
lected and analyzed for the presence of cytokines. All CDC
cultures were in equivalent cell number/volume of media
ratio. Media were centrifuged at 2000 rcf for 5 minutes and
then stored at −80°C until analysis. Media were analyzed
by a membrane-based ELISA (RayBio® Human Cytokine
Antibody Array 5; RayBiotech, Norcross, GA, USA), accord-
ing to the manufacturer’s instructions. Densitometric analy-
sis was performed by ImageJ software, and data is presented
as optical density values normalized to the assay’s internal
positive control.
2.7. Statistical Analysis. All results are presented as mean
value± standard error of the mean, unless speciﬁed. Signiﬁ-
cance of diﬀerence between any two groups was determined
by two-sided Student’s t-test, and a ﬁnal value of p < 0 05
was considered signiﬁcant.
3. Results
We obtained decellularized matrix, named cardiogel (CG),
from conﬂuent cultures of endogenous CFs, isolated from
biopsies of normal (CG-N) or pathological (CG-P) heart tis-
sue, as previously described [25]. CPCs were isolated from
cardiospheres as CDCs, as an established spheroid culture
system to isolate progenitor cells from solid tissues [27, 32].
CDCs were plated and grown for 7 days on the two diﬀerent
substrates, CG-N and CG-P, and on standard ﬁbronectin-
coated dishes as the control. We assessed the expression
levels of three panels of marker genes related to CPC pheno-
type, epithelial-to-mesenchymal transition, and cardiovascu-
lar commitment and diﬀerentiation. We observed a
signiﬁcant increase in the expression of the cardiac-speciﬁc
transcription factor NK2 homeobox 5 (NKX2-5) in both
CGs and control (Figure 1(a)), suggesting that the cells are
subjected to more physiological and cardiogenic stimuli by
the substrates. We observed also a signiﬁcant upregulation
of the connexin 43 gene expression (CX43) in both cardiogels
compared to FN-coated controls (Figure 1(a)), suggesting a
cardiac diﬀerentiation-supportive signal from both CGs
compared to standard culture conditions. The results for all
other cardiovascular genes analyzed showed trends without
reaching statistically signiﬁcant changes. Concerning EMT-
related genes, we could observe a slight modulation among
samples of β-catenin (CTNNB1) and vimentin (VIM)
expression (Figure 1(b)). We evaluated the percentage of
CD90+ cells by ﬂow cytometry, since this parameter has been
linked to lower performance of the CDC cellular product in
cell therapy approaches [33, 34], and found that the CD90+
subpopulation was comparable among samples from both
cardiogels (Figure 2). We also analyzed in the same samples
the proportion of CD117+ cells, as a proposed marker for
CPCs [35], and it was unaﬀected (data not shown). Next,
we investigated by immunoﬂuorescence staining whether the
protein abundance or distribution of markers related to stem-
ness and cardiac commitment could be modulated by the
diﬀerent substrates (Figure 3). The percentage of cells positive
for the transcription factors POU class 5 homeobox 1 (OCT-
4), NKX2-5, and GATA-binding protein 4 (GATA4) was not
aﬀected by culture substrates (Supplementary Figure 1 avail-
able online at https://doi.org/10.1155/2017/7396462), as
Table 1: Primers used for qPCR analyses.
GAPDH fw ACAGTCAGCCGCATCTTC
GAPDH rv GCCCAATACGACCAAATCC
Nkx2.5 fw GGTGGAGCTGGAGAAGACAGA
Nkx2.5 rv CGCCGCTCCAGTTCATAG
GATA-4 fw GTTTTTTCCCCTTTGATTTTTGATC
GATA-4 rv AACGACGGCAACAACGATAAT
Cx43 Fw AGGAGTTCAATCACTTGGCG
Cx43 Rv GAGTTTGCCTAAGGCGCTC
Thy-1 fw CAGCGGAAGACCCCAGT
Thy-1 rv CGTTAGGCTGGTCACCTTCT
ACTC1 fw GTACCCTGGTATTGCTGATCG
ACTC1 rv CCTCATCGTACTCTTGCTTGCT
TTN fw CCTTGCCTGACACACCAGAT
TTN rv GGTGCTGGTACTCTTGCTGT
CTNNB1 fw AGGTCTGAGGAGCAGCTTCA
CTNNB1 rv ATTGTCCACGCTGGATTTTC
Snai1 fw CTTCTCTAGGCCCTGGCTG
Snai1 rv CATCTGAGTGGGTCTGGAGG
TGFBR2 fw CTGCACATCGTCCTGTGG
TGFBR2 rv GGAAACTTGACTGCACCGTT
Vim rv ACCCACTCAAAAAGGACACTTC
Vim fw GGTCATCGTGATGCTGAGAA
ACTA1fw ATGAAGATCCTGACTGAGCG
ACTA1 rv GCAGTGGCCATCTCATTTTC
KDR fw AAAGGGTGGAGGTGACTGAG
KDR rv CGGTAGAAGCACTTGTAGGC
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well as the proportion and morphology of VIM-positive
and α-smooth muscle actin (ACTA1)-positive cells
(Figure 3). Instead, we observed a staining pattern of con-
nexin 43 and vascular endothelial growth factor receptor
(KDR), showing an increase in these protein expression
in cells cultured on cardiogels (Figure 3).
CDCs have been shown to exert paracrine beneﬁcial
eﬀects [36–38]; therefore, we investigated whether culture
on CGs could diﬀerentially inﬂuence their secretion proﬁle.
We screened 24 hour-conditioned media by protein arrays
and detected the modulation of several humoral factors on
the diﬀerent substrates (Figure 4(a)). Most of the cytokines
were not diﬀerentially secreted in conditioned media
collected from CG-N and CG-P cultures. Nonetheless, osteo-
pontin, ﬁbroblast growth factor 6 (FGF6), ﬁbroblast growth
factor 7 (FGF7), neurotrophin 3 (NT-3), insulin-like growth
factor-binding protein 4 (IGFBP4), and tissue inhibitor of
metalloproteinases 2 (TIMP2) levels were signiﬁcantly
upregulated in CG-N-conditioned media compared to CG-
P-conditioned media (Figure 4(b)).
4. Discussion
One major topic of interest in the ﬁeld of CPC biology is how
their diﬀerentiation potential may be inﬂuenced by changes
in ECM features during both normal aging and HF
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Figure 1: Relative gene expression levels of CDCs grown on normal (CG-N) and pathological cardiogel (CG-P). Bar graphs showing gene
expression change in a panel of cardiac diﬀerentiation and commitment (a) and mesenchymal (b) genes. Both CG-N and CG-P CDCs
displayed signiﬁcantly higher expression levels of the cardiac-speciﬁc genes NKX2-5 and CX43 (a) compared to CDCs grown on
ﬁbronectin used as the control. Only CTNNB (beta catenin) and VIM (b) were signiﬁcantly upregulated in CG-N and CG-P CDCs,
respectively, compared to the control (n = 3). CG-N: normal cardiogel; CG-P: pathological cardiogel; ACTC1: cardiac muscle actin alpha;
TTN: titin. ∗∗p < 0 01, ∗p < 0 05.
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Figure 2: CD90-positive CDC immunophenotype on diﬀerent cardiogel substrates. Representative histogram of ﬂow cytometry analysis. The
immunophenotypes of CG-N and CG-P CDCs were not signiﬁcantly diﬀerent concerning the abundance of the CD90+ subpopulation, as
shown by the representative ﬂow cytometry histograms. CG-N: normal cardiogel; CG-P: pathological cardiogel.
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remodelling. These two conditions may have additive eﬀects
on the reduction in the stemness potential of resident CPCs
[39], which may conversely aﬀect ECM homeostasis and
remodelling. Thus, it is important to understand the mecha-
nisms of the bidirectional relationship between ECM and
CPCs, because the presence of pathological ECM in a site of
cell therapy delivery/engraftment may hamper the
regenerative potential of resident progenitors, as well as that
of exogenous transplanted CPCs, through detrimental bio-
mechanical signals [19, 40], altering their cardiogenic/ﬁbrotic
balance [41]. Consistently, despite the abundance and thera-
peutic phenotype of CPCs isolated from advanced HF
patients [42], the diﬀerentiation process of resident CPCs
has been demonstrated to slow down in pathological
ACTA1
OCT4
NKX2.5
GATA4
VIM
FN CG-N CG-P
CX43
KDR
Figure 3: Immunoﬂuorescence phenotype of CDCs from normal and pathological cardiogels. Representative CDC immunoﬂuorescence
images showing no diﬀerences in the distribution of the proteins ACTA1, GATA4, NKX2.5, OCT4, and VIM between cells grown on CG-
N and CG-P. The protein expression of Cx43 and KDR increases in CDCs cultured on cardiogel. Scale bars = 100μm. FN: ﬁbronectin;
CG-N: normal cardiogel; CG-P: pathological cardiogel.
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conditions, with higher accumulation of progenitors versus
precursors [43]. In the present study, we investigate the
eﬀects on CDC phenotype (which is a clinically relevant cell
population containing CPCs [28]) elicited by an ex vivo car-
diac ﬁbroblast-derived decellularized ECM substrate, named
cardiogel, laid by CFs isolated either from normal (healthy)
or from pathological heart tissue. This substrate has been
previously characterized; it is made of several diﬀerent
endogenous cardiac proteins, with a higher protein content
in laminin, tenascin, and collagen I when produced by path-
ological CFs, and induces a higher proliferation of primitive
CD117+ cardiac cells [25]. Here, we report that the pheno-
type of CPCs is partially aﬀected by culture on cardiogels;
speciﬁcally, we observed upregulated gene expression of
NKX2-5 and CX43, similar on both substrates as compared
to standard culture conditions. However, this transcriptional
modulation was conﬁrmed by immunostaining for CX43
protein only. In addition, despite KDR gene expression
change in CGs does not reach statistical signiﬁcance, the
protein level is increased in cells grown on both cardiogel
substrates. These results suggest a partial commitment eﬀect
of the cardiogels on CDCs. The analysis of indicators of mes-
enchymal ﬁbroblast-like phenotype revealed no signiﬁcant
modulation at the transcriptional level, except for a slight
increase in vimentin gene expression in CG-P, although not
mirrored by evident modulation in the corresponding
protein level or distribution. Also, the CD90+ subpopulation
proportion, the only immunophenotypical trait reported so
far to signiﬁcantly impair the therapeutic potential of CDCs
[33] and to be associated with features of a ﬁbrotic-prone
phenotype [17, 34], was not aﬀected by the diﬀerent
substrates. Overall, these data suggest that the cardiogel sub-
strates tested do not change, at least in the short term, the
phenotypic traits within the CDC pool or their ability to
undergo type 2 EMT [44] towards a ﬁbrotic phenotype.
CPCs exert therapeutic eﬀects through both direct and
indirect mechanisms, such as cardiovascular diﬀerentiation
and paracrine eﬀects [36–38]. Interestingly, culture on CG-
N was associated with signiﬁcant upregulation of some
secreted cytokines of interest compared to that on CG-P, all
of which have been shown to exert positive eﬀects on cardiac
cell types in diﬀerent contexts. The release of TNF-α by CPCs
was the only one reduced on CG-N compared to CG-P, and
since it is a main inﬂammatory mediator of ischemic injury
[45] and a potential target of beneﬁcial cell therapy mecha-
nisms [46], this reduction is consistently associated with the
more physiological substrate (CG-N). Concerning the cyto-
kines secreted at higher levels in CG-N, the FGF family in
mammals comprises many diﬀerent proteins, where FGF2,
FGF16, FGF21, and FGF23 are the main forms known to reg-
ulate cardiac physiology and pathophysiology [47]. Despite
the fundamental homeostatic roles of FGF family isoforms,
such as FGF2, in the heart [48, 49], to the best of our knowl-
edge, many other members of the FGF family, including
FGF6 and FGF7, have not been directly associated with any
cardiac condition. Nonetheless, it has been reported that
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Figure 4: Screening of conditioned media from CG-N and CG-P CDCs for paracrine molecules. (a) Representative blots from protein arrays
of CDC-conditioned media. A selection of growth factors, chemokines, and cytokines of interest is highlighted in the panel. Diﬀerential
analysis of conditioned media from CG-N and CG-P CDCs revealed a distinctive modulation in the secretion proﬁle of a subset of
cytokines, as plotted in (b). OD: optical density; CG-N: normal cardiogel; CG-P: pathological cardiogel.
6 Stem Cells International
FGF6 has a dual function in muscle regeneration, stimulating
myoblast proliferation/migration and muscle diﬀerentia-
tion/hypertrophy in a dose-dependent way. Moreover, FGF6
has been suggested to play a role in the maintenance of a
progenitor cell pool in the skeletalmuscle [50].Wemight spec-
ulate that similar mechanisms may be active also in the heart.
Osteopontin, instead, is known to be upregulated in multiple
tissues, including those in the heart, in response to injury and
inﬂammation [51], and its balanced release has been described
to sustain impaired angiogenesis during tissue repair after
infarction [52]. NT-3 downregulation, instead, is associated
with impaired sympathetic function in the heart during the
progression of heart failure [53], suggesting that CPCs grown
on CG-N may be more prone to counteract this detrimental
mechanism. Moreover, TIMP-2 release was also increased on
CG-N versus CG-P. TIMP-2 is an MMP inhibitor acting as
an antiremodelling secreted protein. Increased MMP activity
has been associated with HF progression [54], and TIMPs
are currently proposed as novel biomarkers of positive
prognosis [55], thus supporting the potential anti-ECM
remodelling eﬀect of CPCs when in contact with CG-N, that
is, ECMlaidbyﬁbroblasts fromhealthy cardiac tissue. IGFBP4
is an IGF1-binding protein regulating the bioavailability of
IGF1, which is a pathway previously described to be active in
CPCs [36], and highly regulated particularly in 3D spheroid
culture conditions [56]. It is noteworthy that IGF1 and
IGFBP4 expression has been reported to be upregulated
during cardiac benign reverse remodelling processes [57],
consistently with the overall antiremodelling CPC proﬁle on
CG-N supported by all the above-mentioned secreted factors.
A clinically relevant correlation has been recently reported
in humans between medical parameters associated, among
others, with antiﬁbrotic properties of resident CPCs and
the reversal of maladaptive cardiac remodelling processes
[17, 58, 59]. This further strengthens the model of bidirec-
tional positive reinforcement between antiremodelling
features of resident CPCs and beneﬁcial ECM properties
in pathological cardiac conditions. Further studies will be
needed to assess how CG-N and CG-P may aﬀect the biology
of other cardiac cell types.
In conclusion, our results show that a human cardiac
ﬁbroblast-derived ECM substrate from HF tissue, that is,
CG-P, does not directly aﬀect short-term the phenotype of
resident CPCs but nonetheless is associated with a more
proﬁbrotic and proremodelling paracrine proﬁle of CPCs.
These observations provide important novel insights into
(1) the interplay between CPC and cardiac ECM; (2) how
HF progression may aﬀect the resident CPC pool through
changes in ECM properties, and vice versa; and (3) how the
remodelled ECM microenvironment of recipient hearts
may negatively aﬀect the paracrine proﬁle of engrafted exog-
enous CPCs in cardiac cell therapy approaches.
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